drugset / Trial / NCT00921115

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

NCT00921115

NaSingle-groupOpen-labelTreatment

Summary

This study is being done to test the safety and effectiveness of two drugs, Anastrozole and Fulvestrant, used as combined therapy in the neo-adjuvant setting for hormone receptor positive invasive breast cancer.

Timeline

Start
2009-05
Primary completion
2015-04
Completion
2023-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Subject Fulvestrant Small molecule 500 mg Intramuscular